SDZ logo

Sandoz Group AG Stock Price

SWX:SDZ Community·CHF 21.3b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 46 Fair Values set on narratives written by author
Create a narrative

SDZ Share Price Performance

CHF 49.49
11.58 (30.55%)
18.0% undervalued intrinsic discount
CHF 60.37
Fair Value
CHF 49.49
11.58 (30.55%)
18.0% undervalued intrinsic discount
CHF 60.37
Fair Value
Price CHF 49.49
AnalystHighTarget CHF 60.37
AnalystConsensusTarget CHF 49.39
AnalystLowTarget CHF 38.02

SDZ Community Narratives

AnalystHighTarget·
Fair Value CHF 60.37 19.6% undervalued intrinsic discount

Rising Healthcare Demand And Aging Populations Will Accelerate Biosimilar Adoption

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value CHF 49.39 1.7% undervalued intrinsic discount

Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities

0users have liked this narrative
0users have commented on this narrative
28users have followed this narrative
AnalystLowTarget·
Fair Value CHF 38.02 27.7% overvalued intrinsic discount

Rising Regulatory Hurdles And US Tariffs Will Undermine Biosimilar Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent SDZ News & Updates

Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities

Key Takeaways Accelerated biosimilar launches, improved manufacturing, and strong market share are driving margin expansion and long-term profitability. Strategic focus on international growth and a robust product pipeline positions the company for sustainable earnings momentum.

Sentiment Still Eluding Sandoz Group AG (VTX:SDZ)

Jun 25
Sentiment Still Eluding Sandoz Group AG (VTX:SDZ)

Is Sandoz Group (VTX:SDZ) A Risky Investment?

Apr 15
Is Sandoz Group (VTX:SDZ) A Risky Investment?

It's A Story Of Risk Vs Reward With Sandoz Group AG (VTX:SDZ)

Mar 07
It's A Story Of Risk Vs Reward With Sandoz Group AG (VTX:SDZ)

Sandoz Group AG Key Details

US$10.6b

Revenue

US$5.6b

Cost of Revenue

US$5.0b

Gross Profit

US$4.7b

Other Expenses

US$227.0m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
0.53
Gross Margin
46.82%
Net Profit Margin
2.14%
Debt/Equity Ratio
60.4%

Sandoz Group AG Competitors

 
 
 
 
 
 
 
 
 
 
 
 
View more competitors

Snowflake Analysis

Reasonable growth potential and slightly overvalued.

1 Risk
3 Rewards
View Full Analysis

About SDZ

Founded
1886
Employees
20000
CEO
Richard Saynor
WebsiteView website
www.sandoz.com

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

Market Insight

Header cover image

📈 Markets Break Records: Q3 2025 in Review, Q4 Outlook Ahead

Richard Bowman avatarRichard Bowman
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Last Week
✨Rare Earths: Tiny Market, Outsized Influence

✨Rare Earths: Tiny Market, Outsized Influence

Swiss Market Performance

  • 7 Days: 1.6%
  • 3 Months: 4.2%
  • 1 Year: 3.6%
  • Year to Date: 7.0%
The market is up 1.6% over the last week, with the Healthcare sector leading the way, up 2.9%. As for the past 12 months, the market is up 3.6%. Looking forward, earnings are forecast to grow by 11% annually. Market details ›